Viking Therapeutics, Inc. (VKTX) reported positive topline results from a maintenance study of its obesity drug candidate VK2735, showing that patients were able to maintain most of their weight loss even after switching from weekly treatment to less frequent dosing schedules.
The findings highlight the potential of VK2735 to offer greater flexibility for long-term obesity management, an area that remains a key challenge for patients requiring ongoing treatment.
Obesity is a chronic condition that often requires sustained treatment to achieve and maintain weight loss. While newer GLP-1 based therapies have demonstrated substantial weight-reduction benefits, maintaining those results over the long term and ensuring treatment adherence remain important considerations for both patients and healthcare providers.
The maintenance study evaluated VK2735, Viking's dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
The investigational therapy is being developed in both injectable and oral formulations for the potential treatment of obesity and other metabolic disorders.
According to the company, patients who received weekly ...